Hosted on MSN21h
Needham Upgrades Collegium Pharmaceutical (COLL)
Fintel reports that on January 10, 2025, Needham upgraded their outlook for Collegium Pharmaceutical (NasdaqGS:COLL) from ...
Collegium's Revenue Outlook And CNS Expansion Signal Undervalued Opportunity, Says Needham
Needham analyst upgrades Collegium Pharmaceutical to Buy with a $46 target, citing strong 2025 guidance, growth potential, ...
Collegium Pharmaceutical’s Promising Growth and Undervalued Potential: A Buy Rating by Serge Belanger
In a report released today, Serge Belanger from Needham upgraded Collegium Pharmaceutical (COLL – Research Report) to a Buy, with a price ...
Collegium Pharmaceutical’s Promising Growth and Strong Financials Drive Buy Rating
In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on Collegium Pharmaceutical (COLL – Research Report), with ...
Pharma companies welcome new year with 583 drug price hikes so far
Drugmakers have started 2025, implementing price hikes for 583 products within the first two days of the new year alone, ...
Collegium Pharmaceutical Unveils 2025 Financial Projections
The latest announcement is out from Collegium Pharmaceutical ( (COLL) ). Collegium Pharmaceutical announced its 2025 financial guidance, projecting product revenues between $735 and $750 million, with ...
Collegium Provides 2025 Financial Guidance and Business Update
Product Revenues, Net Expected in the Range of $735 Million to $750 Million – – Jornay PM® Net Revenue Expected to be in ...